CTi Biopharma Corp Financials

Based on the key measurements obtained from CTi Biopharma's financial statements, CTi Biopharma Corp is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.
  
Understanding current and past CTi Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CTi Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in CTi Biopharma's assets may result in an increase in income on the income statement.
Please note, the presentation of CTi Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CTi Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CTi Biopharma's management manipulating its earnings.

CTi Biopharma Stock Summary

CTi Biopharma competes with Rigel Pharmaceuticals, Fortress Biotech, Reviva Pharmaceuticals, Protalix Biotherapeutics, and Seres Therapeutics. CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Cti Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS12648L6011
Business Address3101 Western Avenue,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.ctibiopharma.com
Phone206 282 7100
CurrencyUSD - US Dollar

CTi Biopharma Key Financial Ratios

CTi Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining CTi Biopharma's current stock value. Our valuation model uses many indicators to compare CTi Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CTi Biopharma competition to find correlations between indicators driving CTi Biopharma's intrinsic value. More Info.
CTi Biopharma Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CTi Biopharma's earnings, one of the primary drivers of an investment's value.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in CTi Stock

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk